Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Replimune Group

DB:7R8
Snowflake Description

Excellent balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
7R8
DB
$413M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
  • Replimune Group has significant price volatility in the past 3 months.
7R8 Share Price and Events
7 Day Returns
10.4%
DB:7R8
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-25.6%
DB:7R8
-7.4%
DE Biotechs
-14.2%
DE Market
7R8 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Replimune Group (7R8) 10.4% -11.4% -30.8% -25.6% - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 7R8 underperformed the Biotechs industry which returned -7.4% over the past year.
  • 7R8 underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

7R8 Value

 Is Replimune Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Replimune Group to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Replimune Group.

DB:7R8 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:7R8
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 21%) (10.17%))
1.089
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.09
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.089 * 5.44%)
5.53%

Discounted Cash Flow Calculation for DB:7R8 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Replimune Group is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:7R8 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.53%)
2020 -68.75 Analyst x2 -65.15
2021 -64.65 Analyst x2 -58.05
2022 -79.70 Analyst x1 -67.81
2023 -91.60 Analyst x1 -73.85
2024 19.80 Analyst x1 15.13
2025 37.30 Analyst x1 27.00
2026 51.99 Est @ 39.38% 35.66
2027 66.26 Est @ 27.45% 43.07
2028 78.91 Est @ 19.1% 48.61
2029 89.37 Est @ 13.25% 52.16
Present value of next 10 years cash flows $-43.00
DB:7R8 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $89.37 × (1 + -0.39%) ÷ (5.53% – -0.39%)
$1,503.19
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,503.19 ÷ (1 + 5.53%)10
$877.33
DB:7R8 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-43.00 + $877.33
$834.33
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $834.33 / 36.65
$22.77
DB:7R8 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:7R8 represents 0.89539x of NasdaqGS:REPL
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.89539x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 22.77 x 0.89539
€20.39
Value per share (EUR) From above. €20.39
Current discount Discount to share price of €10.10
= -1 x (€10.10 - €20.39) / €20.39
50.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Replimune Group is available for.
Intrinsic value
>50%
Share price is €10.1 vs Future cash flow value of €20.39
Current Discount Checks
For Replimune Group to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Replimune Group's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Replimune Group's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Replimune Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Replimune Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:7R8 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.34
NasdaqGS:REPL Share Price ** NasdaqGS (2020-04-08) in USD $11.28
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Replimune Group.

DB:7R8 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:REPL Share Price ÷ EPS (both in USD)

= 11.28 ÷ -1.34

-8.41x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Replimune Group is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Replimune Group is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Replimune Group's expected growth come at a high price?
Raw Data
DB:7R8 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.41x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-6.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Replimune Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Replimune Group's assets?
Raw Data
DB:7R8 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $5.39
NasdaqGS:REPL Share Price * NasdaqGS (2020-04-08) in USD $11.28
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:7R8 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:REPL Share Price ÷ Book Value per Share (both in USD)

= 11.28 ÷ 5.39

2.09x

* Primary Listing of Replimune Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Replimune Group is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Replimune Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Replimune Group has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

7R8 Future Performance

 How is Replimune Group expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-6.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Replimune Group expected to grow at an attractive rate?
  • Unable to compare Replimune Group's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Replimune Group's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Replimune Group's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:7R8 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:7R8 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -6.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:7R8 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:7R8 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2025-03-31 422 37 -24 3
2024-03-31 177 20 -128 3
2023-03-31 71 -92 -126 3
2022-03-31 5 -80 -95 5
2021-03-31 2 -66 -74 6
2020-04-09
2020-03-31 0 -53 -53 6
DB:7R8 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -55 -43
2019-09-30 -46 -35
2019-06-30 -32 -30
2019-03-31 -25 -31
2018-12-31 -24 -31
2018-09-30 -20 -28
2018-06-30 -17 -26
2018-03-31 -16 -20
2017-12-31 -15 -17
2017-03-31 -7 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Replimune Group is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Replimune Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:7R8 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Replimune Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7R8 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2025-03-31 -0.49 -0.27 -0.70 2.00
2024-03-31 -2.67 -1.86 -3.47 2.00
2023-03-31 -2.66 -2.42 -2.89 2.00
2022-03-31 -2.24 -2.05 -2.53 3.00
2021-03-31 -1.91 -1.43 -2.22 5.00
2020-04-09
2020-03-31 -1.58 -1.53 -1.61 5.00
DB:7R8 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.34
2019-09-30 -1.11
2019-06-30 -1.01
2019-03-31 -1.33
2018-12-31 -1.87
2018-09-30 -2.83
2018-06-30 -5.26
2018-03-31 -3.96
2017-12-31 -3.36
2017-03-31 -1.55

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Replimune Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Replimune Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Replimune Group has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

7R8 Past Performance

  How has Replimune Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Replimune Group's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Replimune Group does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Replimune Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Replimune Group's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Replimune Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Replimune Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7R8 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -43.49 14.65 30.20
2019-09-30 -34.98 12.21 25.49
2019-06-30 -30.30 10.28 22.98
2019-03-31 -30.83 8.77 19.65
2018-12-31 -31.03 8.92 18.70
2018-09-30 -28.00 7.81 15.45
2018-06-30 -26.19 6.77 12.92
2018-03-31 -19.70 5.71 11.25
2017-12-31 -16.72 4.39 9.34
2017-03-31 -7.70 2.71 5.49

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Replimune Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Replimune Group has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Replimune Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Replimune Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Replimune Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

7R8 Health

 How is Replimune Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Replimune Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Replimune Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Replimune Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Replimune Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 19.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Replimune Group Company Filings, last reported 3 months ago.

DB:7R8 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 197.57 9.74 180.88
2019-09-30 120.64 9.66 109.88
2019-06-30 130.15 0.00 120.80
2019-03-31 137.86 6.56 134.81
2018-12-31 143.24 0.00 141.80
2018-09-30 150.04 0.00 147.89
2018-06-30 54.75 0.00 52.03
2018-03-31 59.94 0.00 61.55
2017-12-31 65.77 0.00 65.03
2017-03-31 20.76 0.00 20.59
  • Replimune Group's level of debt (4.9%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Replimune Group's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Replimune Group has sufficient cash runway for 2.9 years based on current free cash flow.
  • Replimune Group has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 66% each year.
X
Financial health checks
We assess Replimune Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Replimune Group has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

7R8 Dividends

 What is Replimune Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Replimune Group dividends.
If you bought €2,000 of Replimune Group shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Replimune Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Replimune Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:7R8 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:7R8 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2025-03-31
2024-03-31
2023-03-31
2022-03-31
2021-03-31
2020-04-09
2020-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Replimune Group has not reported any payouts.
  • Unable to verify if Replimune Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Replimune Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Replimune Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Replimune Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Replimune Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Replimune Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

7R8 Management

 What is the CEO of Replimune Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Philip Astley-Sparke
COMPENSATION $1,812,591
AGE 48
TENURE AS CEO 0.3 years
CEO Bio

Mr. Philip Astley-Sparke, FSA, is a Co-founder of Replimune Group, Inc. and served as its Executive Chairman since 2015 until April 2, 2020. Mr. Astley-Sparke is Secretary and Treasurer at Replimune Group, Inc. and serves as its Chief Executive Officer since January 2020. Mr. Astley-Sparke has been Venture Partner at Forbion Capital Partners since May 2012. He has extensive experience developing biotechnology companies from the research stage to pre-launch, as well as experience in commercial planning, including setting up commercial scale manufacturing. Mr. Astley-Sparke served as the President of US Operations at uniQure N.V. since January 2013 until February 2015. He provided strategic leadership and helped build uniQure's clinical, regulatory and commercial infrastructure in the United States. He served as a Vice President and General Manager at Amgen, Inc. until December 2011. He served as Executive at JPMorgan Chase & Co. He served as the President of BioVex, Inc. since July 2005, Chief Executive Officer since 2005 and its Chief Financial Officer since 2000. He successfully implemented exit strategy when the firm was being acquired by Amgen. In 2005, he established Biovex’ US operations from scratch; recruiting the entire US senior management team (outside the CTO) whilst setting up all key functions including commercial capabilities. He grew the Company to 70 employees in Woburn, MA while retaining 30 in Abingdon, UK. He served as an Investment Banker of JP Morgan H&Q (Robert Fleming), where he advised on a number of high profile mergers and public financings. Over the years, he executed five major equity financings involving blue chip international investor syndicates totaling more than $160m including the second largest biotech VC raise of 2009 at $70 million. He also oversaw the building of a launch grade manufacturing facility to zero default timelines and led his team through the agreement of a SPA with the FDA on the design of a pivotal study which commenced and was recruited on projected timeframes. Mr. Astley-Sparke serves as the Non-Executive Chairman of Oxyrane UK Limited. He has been the Chairman of uniQure N.V. since September 22, 2016 and its Director since June 15, 2015. He served as Member of Supervisory Board at uniQure N.V. since June 10, 2015 until June 15, 2016. He served as Chairman of BioVex Inc from November 2009 to March 2011. He served as a Director of BioVex, Inc. since 2000. He qualified as a Chartered Accountant with Arthur Andersen and holds FSA. He holds a Bachelor’s Degree in Cellular Pathology and Molecular Pathology from Bristol University (UK).

CEO Compensation
  • Philip's compensation has increased whilst company is loss making.
  • Philip's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Replimune Group management team in years:

4.4
Average Tenure
53.5
Average Age
  • The tenure for the Replimune Group management team is about average.
Management Team

Philip Astley-Sparke

TITLE
CEO, Secretary
COMPENSATION
$2M
AGE
48
TENURE
0.3 yrs

Rob Coffin

TITLE
Founder
COMPENSATION
$2M
AGE
54
TENURE
5.3 yrs

Colin Love

TITLE
Chief Operating Officer
COMPENSATION
$1M
AGE
61
TENURE
4.5 yrs

Jean Franchi

TITLE
Chief Financial Officer
AGE
53
TENURE
0.3 yrs

Stephen Gorgol

TITLE
Chief Accounting Officer
AGE
60

Pamela Esposito

TITLE
Chief Business Officer
COMPENSATION
$601K
AGE
44
TENURE
4.4 yrs
Board of Directors Tenure

Average tenure and age of the Replimune Group board of directors in years:

4.8
Average Tenure
54
Average Age
  • The tenure for the Replimune Group board of directors is about average.
Board of Directors

Dieter Weinand

TITLE
Independent Chairman of the Board
COMPENSATION
$263K
AGE
59

Philip Astley-Sparke

TITLE
CEO, Secretary
COMPENSATION
$2M
AGE
48
TENURE
5.3 yrs

Rob Coffin

TITLE
Founder
COMPENSATION
$2M
AGE
54
TENURE
5.3 yrs

Kapil Dhingra

TITLE
Independent Director
COMPENSATION
$156K
AGE
60
TENURE
2.8 yrs

Jason Rhodes

TITLE
Independent Director
COMPENSATION
$151K
AGE
49
TENURE
4.6 yrs

Joe Slattery

TITLE
Lead Independent Director
COMPENSATION
$159K
AGE
54
TENURE
1.1 yrs

Hy Levitsky

TITLE
Independent Non-Executive Director
COMPENSATION
$263K
AGE
61
TENURE
1.9 yrs

Sander Slootweg

TITLE
Independent Director
COMPENSATION
$144K
AGE
51
TENURE
5.3 yrs

Otello Stampacchia

TITLE
Independent Director
COMPENSATION
$118K
AGE
45
TENURE
4.9 yrs

Paolo Pucci

TITLE
Director
AGE
58
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
20. Nov 19 Buy Atlas Venture L.P. Company 18. Nov 19 18. Nov 19 1,100,000 €12.27 €13,502,345
20. Nov 19 Buy Omega Fund Management, LLC Company 18. Nov 19 18. Nov 19 220,000 €12.27 €2,700,469
X
Management checks
We assess Replimune Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Replimune Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

7R8 News

Simply Wall St News

7R8 Company Info

Description

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. It is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Details
Name: Replimune Group, Inc.
7R8
Exchange: DB
Founded: 2015
$380,128,552
36,645,650
Website: http://www.replimune.com
Address: Replimune Group, Inc.
18 Commerce Way,
Woburn,
Massachusetts, 01801,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS REPL Common Stock Nasdaq Global Select US USD 20. Jul 2018
DB 7R8 Common Stock Deutsche Boerse AG DE EUR 20. Jul 2018
Number of employees
Current staff
Staff numbers
104
Replimune Group employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 01:12
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/06
Last earnings filing: 2020/02/13
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.